Septerna, Inc. (SEPN) shareholders
Close on Nov 17, 2026Market cap $1.87BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Trv Gp V, LLC Joint filing with Third Rock Ventures V, L.P. (14.00%), Third Rock Ventures GP V, L.P. (14.00%) and 3 more | 6,215,591 | 14.00% | 13G (passive) amendment | Mar 31, 2025 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (11.80%), Rajeev Shah (11.80%) and 1 more | 5,525,324 | 11.80% | 13D (active) amendment | Aug 12, 2026 |
| Driehaus Capital Management LLC | 4,433,058 | 9.83% | 13G (passive) amendment | Jun 30, 2026 |
| Lampert Mark N Joint filing with Bvf Partners L P/Il (9.90%), Bvf Inc/Il (9.90%) and 3 more | 4,396,124 | 9.90% | 13G (passive) amendment | Mar 31, 2025 |
| Samsara BioCapital, L.P. Joint filing with Samsara BioCapital GP, LLC (6.20%), Srinivas Akkaraju (6.20%) | 2,768,520 | 6.20% | 13G (passive) | Oct 28, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SEPN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 6,995,858 | 14.99% | $234.29M | – | 2.04% |
| Trv Gp V, LLC | 6,215,591 | 13.32% | $208.16M | – | 41.78% |
| Driehaus Capital Management LLC | 4,433,058 | 9.50% | $148.46M | +37,486 | 0.86% |
| Trv Gp Vi, LLC | 4,211,659 | 9.02% | $141.05M | – | 60.72% |
| Samsara BioCapital, LLC | 3,149,128 | 6.75% | $105.46M | – | 8.66% |
| Goldman Sachs Group Inc | 3,062,766 | 6.56% | $102.57M | +156,339 | 0.01% |
| BlackRock, Inc. | 1,932,088 | 4.14% | $64.71M | +109,914 | 0.00% |
| Siren, L.L.C. | 1,900,000 | 4.07% | $63.63M | −100,000 | 1.29% |
| Avoro Capital Advisors LLC | 1,337,500 | 2.87% | $44.79M | – | 0.40% |
| Jupiter Topco LLC | 1,307,500 | 2.80% | $43.72M | New | 0.02% |
| Vanguard Capital Management LLC | 1,221,673 | 2.62% | $40.91M | +24,711 | 0.00% |
| Primecap Management Co/Ca/ | 1,167,382 | 2.50% | $39.10M | +118,548 | 0.02% |
| First Light Asset Management, LLC | 963,260 | 2.06% | $32.26M | +230,400 | 1.96% |
| ADAR1 Capital Management, LLC | 940,747 | 2.02% | $31.51M | −149,071 | 1.44% |
| Geode Capital Management, LLC | 679,163 | 1.46% | $22.75M | +34,017 | 0.00% |
| State Street Corp | 652,630 | 1.40% | $21.86M | +21,183 | 0.00% |
| Loomis Sayles & Co L P | 624,752 | 1.34% | $20.92M | New | 0.03% |
| Casdin Capital, LLC | 553,268 | 1.19% | $18.53M | – | 0.93% |
| Catalio Capital Management, LP | 536,152 | 1.15% | $17.96M | +241,792 | 3.37% |
| Algert Global LLC | 397,487 | 0.85% | $13.31M | +376,452 | 0.16% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 154 | 47M | 100.0% | 48 / 49 | 32 / 16 | 5M | 3M |
| Q1 2026 | 124 | 46M | 98.4% | 28 / 44 | 30 / 24 | 5M | 3M |
| Q4 2025 | 122 | 46M | 97.7% | 45 / 31 | 27 / 5 | 5M | 4M |
| Q3 2025 | 82 | 45M | 95.5% | 10 / 32 | 16 / 16 | 2M | 2M |
| Q2 2025 | 89 | 44M | 95.2% | 25 / 31 | 19 / 6 | 4M | 5M |
| Q1 2025 | 71 | 45M | 97.0% | 20 / 25 | 12 / 19 | 8M | 7M |
| Q4 2024 | 71 | 44M | 94.5% | 71 / 0 | 0 / 0 | 44M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
169 funds held SEPN in Q2 2026, 44% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SEPN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 927,665 | 1.99% | $31.07M | 0.00% | Jun 30, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 824,582 | 1.77% | $28.41M | 0.38% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 578,523 | 1.24% | $19.37M | 0.02% | Jun 30, 2026 |
| Driehaus Small Cap Growth Fund | 417,859 | 0.90% | $13.99M | 0.87% | Jun 30, 2026 |
| Loomis Sayles Small Cap Growth Fund | 338,579 | 0.73% | $11.34M | 0.50% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 261,547 | 0.56% | $8.76M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 242,456 | 0.52% | $8.35M | 0.02% | Jul 31, 2026 |
| iShares Biotechnology ETF | 192,645 | 0.41% | $6.45M | 0.07% | Jun 30, 2026 |
| Driehaus Micro Cap Growth Fund | 158,272 | 0.34% | $5.30M | 0.89% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 138,834 | 0.30% | $4.65M | 0.03% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 126,696 | 0.27% | $4.24M | 0.99% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 116,900 | 0.25% | $3.53M | 0.01% | May 31, 2026 |
| Column Small Cap Select Fund | 110,886 | 0.24% | $3.35M | 0.18% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 109,770 | 0.24% | $3.32M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 108,128 | 0.23% | $3.27M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jeffrey Finer | Chief Executive Officer, Director | 833,909 | 1.79% | Nov 16, 2026 |
| Elizabeth Bhatt | President and COO | 174,209 | 0.37% | Oct 19, 2026 |
| Rajiv Patni | Chief Medical Officer | – | – | Sep 10, 2026 |
| Daniel D. Long | SVP, Drug Discovery | 96,412 | 0.21% | Sep 3, 2026 |
| Samira Shaikhly | Chief People Officer | 793 | 0.00% | Jun 30, 2026 |
| Uwe Klein | SVP, Biological Sciences | 119,912 | 0.26% | Feb 10, 2026 |
| Jae B. Kim | Chief Medical Officer | – | – | Feb 10, 2026 |
| Mark Andrew Wilson | Chief Legal Officer | – | – | Feb 10, 2026 |
| Gil M. Labrucherie | Chief Financial Officer | 40,000 | 0.09% | Feb 10, 2026 |
| Alan Ezekowitz | Director | 35,600 | 0.08% | Nov 13, 2026 |
| Capital Healthcare Fund LP RA | Director, 10% owner | – | – | Aug 14, 2026 |
| Peter Kolchinsky | Director, 10% owner | – | – | Aug 14, 2026 |
| RA Capital Nexus Fund III, L.P. | Director | – | – | Aug 14, 2026 |
| Rajeev M. Shah | Director, 10% owner | 725,443 | 1.55% | Aug 14, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | – | – | Aug 14, 2026 |
| Shalini Sharp | Director | – | – | Jun 30, 2026 |
| Keith Michael Gottesdiener | Director | – | – | Jun 30, 2026 |
| Bernard Coulie | Director | – | – | Jun 30, 2026 |
| Jeffrey K. Tong | Director | – | – | Jun 30, 2026 |
| Abraham Bassan | Director | – | – | Jun 30, 2026 |
| Jake Simson | Director | – | – | Jun 30, 2026 |
| Third Rock Ventures GP VI, L.P. | 10% owner | 10,280,191 | 22.02% | Aug 14, 2026 |
| Trv Gp V, Llc | 10% owner | 12,241,003 | 26.22% | Aug 14, 2026 |
| Third Rock Ventures VI, L.P. | 10% owner | – | – | Aug 14, 2026 |
| Third Rock Ventures GP V, LP | 10% owner | 10,427,250 | 22.34% | Aug 14, 2026 |
| Trv Gp Vi, Llc | 10% owner | – | – | Aug 14, 2026 |
| Third Rock Ventures V, L.P. | 10% owner | – | – | Aug 14, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jeffrey Finer Chief Executive Officer, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −1,977 | $46.16 | $91.26K | 833,909 |
| Jeffrey Finer Chief Executive Officer, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −2,823 | $45.28 | $127.81K | 835,886 |
| Jeffrey Finer Chief Executive Officer, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −2,800 | $44.23 | $123.83K | 838,709 |
| Jeffrey Finer Chief Executive Officer, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −5,300 | $43.10 | $228.41K | 841,509 |
| Jeffrey Finer Chief Executive Officer, Director | Nov 12, 2026 | Sale(10b5-1 plan) | −5,600 | $42.09 | $235.70K | 846,809 |
| Jeffrey Finer Chief Executive Officer, Director | Nov 12, 2026 | Option exercise | +18,500 | $2.76 | $51.06K | 852,409 |
| Alan Ezekowitz Director | Nov 11, 2026 | Sale(10b5-1 plan) | −1,055 | $51.90 | $54.75K | 35,600 |
| Alan Ezekowitz Director | Nov 11, 2026 | Sale(10b5-1 plan) | −2,013 | $50.90 | $102.46K | 36,655 |
| Alan Ezekowitz Director | Nov 11, 2026 | Sale(10b5-1 plan) | −4,175 | $49.65 | $207.27K | 38,668 |
| Alan Ezekowitz Director | Nov 11, 2026 | Sale(10b5-1 plan) | −31,572 | $48.70 | $1.54M | 42,843 |
| Alan Ezekowitz Director | Nov 11, 2026 | Sale(10b5-1 plan) | −22,865 | $47.78 | $1.09M | 74,415 |
| Alan Ezekowitz Director | Nov 11, 2026 | Sale(10b5-1 plan) | −13,201 | $47.01 | $620.60K | 97,280 |
| Alan Ezekowitz Director | Nov 11, 2026 | Sale(10b5-1 plan) | −6,939 | $46.01 | $319.23K | 110,481 |
| Elizabeth Bhatt President and COO | Oct 15, 2026 | Sale(10b5-1 plan) | −2,906 | $37.61 | $109.31K | 174,209 |
| Elizabeth Bhatt President and COO | Oct 15, 2026 | Sale(10b5-1 plan) | −1,094 | $36.87 | $40.34K | 177,115 |
| Elizabeth Bhatt President and COO | Oct 15, 2026 | Option exercise | +4,000 | $6.81 | $27.24K | 178,209 |
| Daniel D. Long SVP, Drug Discovery | Sep 1, 2026 | Sale(10b5-1 plan) | −3,333 | $37.83 | $126.09K | 96,412 |
| Daniel D. Long SVP, Drug Discovery | Sep 1, 2026 | Option exercise | +3,333 | $2.76 | $9.20K | 99,745 |
| Rajeev M. Shah Director, 10% owner | Aug 12, 2026 | Sale | −746,500 | $42.50 | $31.73M | 725,443 |
| Rajeev M. Shah Director, 10% owner | Aug 12, 2026 | Sale | −746,500 | $42.50 | $31.73M | 4,777,415 |
| Third Rock Ventures GP VI, L.P. 10% owner | Aug 12, 2026 | Sale(10b5-1 plan) | +147,059 | $50.27 | $7.39M | 6,068,532 |
| Third Rock Ventures GP VI, L.P. 10% owner | Aug 12, 2026 | Sale(10b5-1 plan) | +141 | $51.08 | $7.20K | 6,068,391 |
| Elizabeth Bhatt President and COO | Aug 11, 2026 | Option exercise | +6,319 | $2.76 | $17.44K | 199,209 |
| Elizabeth Bhatt President and COO | Aug 11, 2026 | Sale(10b5-1 plan) | −25,000 | $44.00 | $1.10M | 174,209 |
| Elizabeth Bhatt President and COO | Aug 11, 2026 | Option exercise | +18,681 | $6.81 | $127.22K | 192,890 |
| Daniel D. Long SVP, Drug Discovery | Aug 3, 2026 | Option exercise | +1,518 | $2.76 | $4.19K | 99,746 |
| Daniel D. Long SVP, Drug Discovery | Aug 3, 2026 | Option exercise | +1,816 | $2.76 | $5.01K | 98,228 |
| Daniel D. Long SVP, Drug Discovery | Aug 3, 2026 | Sale(10b5-1 plan) | −1,000 | $33.98 | $33.98K | 98,746 |
| Daniel D. Long SVP, Drug Discovery | Aug 3, 2026 | Sale(10b5-1 plan) | −2,334 | $34.68 | $80.94K | 96,412 |
| Elizabeth Bhatt President and COO | Jul 15, 2026 | Option exercise | +4,000 | $6.81 | $27.24K | 178,209 |
| Elizabeth Bhatt President and COO | Jul 15, 2026 | Sale(10b5-1 plan) | −4,000 | $33.99 | $135.96K | 174,209 |
| Daniel D. Long SVP, Drug Discovery | Jul 1, 2026 | Sale(10b5-1 plan) | −2,100 | $34.10 | $71.61K | 97,645 |
| Daniel D. Long SVP, Drug Discovery | Jul 1, 2026 | Option exercise | +3,333 | $2.76 | $9.20K | 99,745 |
| Daniel D. Long SVP, Drug Discovery | Jul 1, 2026 | Sale(10b5-1 plan) | −1,233 | $34.81 | $42.92K | 96,412 |
| Samira Shaikhly Chief People Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −2,178 | $35.18 | $76.62K | 793 |
| Samira Shaikhly Chief People Officer | Jun 29, 2026 | Option exercise | +2,178 | $6.81 | $14.83K | 2,971 |
| Daniel D. Long SVP, Drug Discovery | Jun 22, 2026 | Option exercise | +4,471 | $11.70 | $52.31K | 111,412 |
| Daniel D. Long SVP, Drug Discovery | Jun 22, 2026 | Sale(10b5-1 plan) | −8,000 | $35.10 | $280.80K | 103,412 |
| Daniel D. Long SVP, Drug Discovery | Jun 22, 2026 | Sale(10b5-1 plan) | −7,000 | $35.97 | $251.79K | 96,412 |
| Daniel D. Long SVP, Drug Discovery | Jun 22, 2026 | Option exercise | +10,529 | $2.76 | $29.06K | 106,941 |
| Samira Shaikhly Chief People Officer | Jun 12, 2026 | Sale(10b5-1 plan) | −6,250 | $35.08 | $219.25K | 793 |
| Samira Shaikhly Chief People Officer | Jun 12, 2026 | Option exercise | +6,250 | $11.70 | $73.13K | 7,043 |
| Samira Shaikhly Chief People Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −1,346 | $28.79 | $38.75K | 3,682 |
| Samira Shaikhly Chief People Officer | Jun 1, 2026 | Option exercise | +4,355 | $1.55 | $6.75K | 5,148 |
| Samira Shaikhly Chief People Officer | Jun 1, 2026 | Option exercise | +943 | $2.76 | $2.60K | 6,091 |
| Samira Shaikhly Chief People Officer | Jun 1, 2026 | Option exercise | +637 | $2.76 | $1.76K | 6,728 |
| Samira Shaikhly Chief People Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −2,889 | $29.66 | $85.69K | 793 |
| Samira Shaikhly Chief People Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −1,700 | $27.78 | $47.23K | 5,028 |
| Samira Shaikhly Chief People Officer | May 26, 2026 | Option exercise | +11,798 | $6.81 | $80.34K | 12,591 |
| Samira Shaikhly Chief People Officer | May 26, 2026 | Sale(10b5-1 plan) | −11,798 | $30.06 | $354.65K | 793 |
| Elizabeth Bhatt President and COO | Apr 15, 2026 | Sale(10b5-1 plan) | −1,101 | $25.24 | $27.79K | 174,535 |
| Elizabeth Bhatt President and COO | Apr 15, 2026 | Option exercise | +4,000 | $6.81 | $27.24K | 178,209 |
| Elizabeth Bhatt President and COO | Apr 15, 2026 | Sale(10b5-1 plan) | −326 | $25.86 | $8.43K | 174,209 |
| Elizabeth Bhatt President and COO | Apr 15, 2026 | Sale(10b5-1 plan) | −2,573 | $23.76 | $61.13K | 175,636 |
| Samira Shaikhly Chief People Officer | Mar 2, 2026 | Option exercise | +53,714 | $1.55 | $83.26K | 54,507 |
| Samira Shaikhly Chief People Officer | Mar 2, 2026 | Option exercise | +11,638 | $2.76 | $32.12K | 66,145 |
| Samira Shaikhly Chief People Officer | Mar 2, 2026 | Option exercise | +5,101 | $2.76 | $14.08K | 71,246 |
| Samira Shaikhly Chief People Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −4,090 | $27.51 | $112.52K | 67,156 |
| Samira Shaikhly Chief People Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −66,363 | $28.14 | $1.87M | 793 |
| Elizabeth Bhatt President and COO | Feb 18, 2026 | Option exercise | +4,000 | $6.81 | $27.24K | 178,209 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Septerna's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,120 shares on Oct 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Daniel D. Long Officer | Oct 1, 2026 | 10,001 | $391.34K | Oct 1, 2026 | Exercise of Stock Options |
| Samira Shaikhly Officer | Oct 1, 2026 | 12,592 | $492.72K | Oct 1, 2026 | Exercise of Stock Options |
| RA Capital Nexus Fund III, L.P. Affiliate | Aug 12, 2026 | 746,500 | $35.97M | Aug 12, 2026 | IPO / Private round |
| Capital Healthcare Fund LP RA affiliate | Aug 12, 2026 | 746,500 | $35.97M | Aug 12, 2026 | IPO |
| Third Rock Ventures V, L.P. 10% Stockholder | Aug 12, 2026 | 147,200 | $7.51M | Aug 12, 2026 | Original Issuance |
| Elizabeth Bhatt Officer | Aug 11, 2026 | 29,000 | $1.13M | Aug 11, 2026 | Exercise of Stock Options |
| Elizabeth Bhatt Officer | Jul 15, 2026 | 4,000 | $138.16K | Jul 15, 2026 | Exercise of Stock Options |
| Jae B. Kim Officer | Jun 26, 2026 | 2,438 | $89.24K | Jun 26, 2026 | Employee Stock Purchase Plan |
| Jae B. Kim Officer | Jun 22, 2026 | 94,339 | $3.33M | Jun 22, 2026 | Stock Option Exercise |
| Daniel D. Long Officer | Jun 22, 2026 | 25,000 | $904.25K | Jun 22, 2026 | Exercise of Stock Options |
| Samira Shaikhly Officer | Jun 12, 2026 | 8,428 | $286.80K | Jun 12, 2026 | Exercise of Stock Options |
| Samira Shaikhly Officer | May 26, 2026 | 11,798 | $334.59K | May 26, 2026 | Exercise of Stock Options |
| Samira Shaikhly Officer | Mar 2, 2026 | 76,388 | $2.22M | Mar 2, 2026 | Exercise of Stock Options |
| Elizabeth Bhatt Officer | Feb 18, 2026 | 8,000 | $242.40K | Feb 18, 2026 | Exercise of Stock Options |
| Daniel D. Long Officer | Nov 10, 2025 | 3,501 | $63.22K | Nov 10, 2025 | Employee Stock Purchase Plan |
See a number that looks wrong?